DEMENTIA DRUGS MARKET ANALYSIS

Dementia Drugs Market, By Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, Glutamate Inhibitor, and Others), By Indication (Alzheimer’s Disease Dementia, Lewy Body Dementia, Parkinson Disease Dementia, and Others), By Route of Administration (Oral, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On September 16, 2024, the Newfoundland and Labrador Dementia-Friendly Communities launched a new website and media campaign aimed at increasing awareness and fostering dementia-inclusive communities. This initiative supports the Dementia Care Action Plan by providing information on services and resources to help individuals and families live well with dementia
On August 22, 2024, Eisai Co., Ltd., a global biopharmaceutical company, and Biogen Inc., a pharmaceutical company, announced that their humanized amyloid-beta monoclonal antibody, Leqembi (lecanemab), had received Marketing Authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. Lecanemab is indicated for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients who are either apolipoprotein E ε4 heterozygotes or non-carriers. This marks it as the first treatment authorized in Europe targeting the underlying causes of early Alzheimer.
On July 2, 2024, Eli Lilly and Company, a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved Kisunla (donanemab-azbt), a once-monthly intravenous injection for adults with early symptomatic Alzheimer's disease. This includes individuals with mild cognitive impairment and mild dementia who have confirmed amyloid pathology. Donanemab aims to address the underlying causes of Alzheimer's disease, marking a significant advancement in treatment options.